Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LadRx Corp stock logo
CYTR
LadRx
$0.09
$0.05
$0.86
$4.14MN/A99,706 shs4,000 shs
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
$1.76
$1.08
$2.45
$131.12M1.19514,103 shs269,400 shs
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
$1.81
+5.8%
$1.70
$0.87
$9.25
$59.75M0.25831,243 shs595,797 shs
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
$3.66
+1.9%
$16.75
$0.70
$3.46
$40.30M1.04648,892 shs635,008 shs
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$4.40
+1.1%
$4.44
$3.03
$14.80
$4.02M1.27138,582 shs18,730 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LadRx Corp stock logo
CYTR
LadRx
0.00%0.00%0.00%0.00%0.00%
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
0.00%0.00%0.00%0.00%0.00%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
0.00%+13.13%-3.21%+50.83%-74.44%
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.00%+16.19%+1.10%+27.53%+62.67%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00%+2.44%-10.39%+16.87%-16.35%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
1.6735 of 5 stars
3.43.00.00.00.60.00.6
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.2945 of 5 stars
0.03.00.00.02.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LadRx Corp stock logo
CYTR
LadRx
0.00
N/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
0.00
N/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2.80
Moderate Buy$9.60430.39% Upside
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.00
N/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TTNP, OTLK, CYTR, LIFE, and TROV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/6/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $21.00
5/20/2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
$350K0.00N/AN/A$1.54 per share0.00
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/A($3.09) per shareN/A
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
$250K161.20N/AN/A$0.94 per share3.89
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$180K22.24N/AN/A$2.67 per share1.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LadRx Corp stock logo
CYTR
LadRx
N/AN/A0.00N/AN/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
-$50.39M-$0.90N/AN/AN/AN/A-56.92%-43.87%N/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$75.37M-$0.91N/AN/AN/AN/AN/A-271.12%8/13/2025 (Estimated)
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
-$16.41M-$2.80N/AN/A-3,688.31%-202.00%-122.92%N/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-$4.71M-$4.59N/AN/AN/A-145.92%-129.20%8/13/2025 (Estimated)

Latest TTNP, OTLK, CYTR, LIFE, and TROV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q2 2025
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A
5/14/2025Q1 2025
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A-$0.62N/A-$0.62N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
N/AN/AN/AN/AN/A
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LadRx Corp stock logo
CYTR
LadRx
N/AN/AN/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
0.02
6.07
6.07
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
N/A
0.72
0.57
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.12
2.37
2.37
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A
7.73
7.73

Institutional Ownership

CompanyInstitutional Ownership
LadRx Corp stock logo
CYTR
LadRx
N/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
61.72%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
11.20%
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
9.99%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
31.49%

Insider Ownership

CompanyInsider Ownership
LadRx Corp stock logo
CYTR
LadRx
N/A
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
3.70%
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
4.80%
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
0.60%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
LadRx Corp stock logo
CYTR
LadRx
N/A45.04 millionN/ANot Optionable
aTyr Pharma, Inc. stock logo
LIFE
aTyr Pharma
5669.01 million66.46 millionOptionable
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
2033.57 million31.96 millionOptionable
Cardiff Oncology, Inc. stock logo
TROV
Cardiff Oncology
N/A11.01 millionN/ANot Optionable
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
10910,000907,000Optionable

Recent News About These Companies

Titan Pharmaceuticals Inc (TTNP) - Investing.com
Titan Pharmaceuticals: Q4 Earnings Snapshot
Titan Pharmaceuticals receives Nasdaq notice of non-compliance
Titan Pharmaceuticals, Inc. (TTNP)
(TTNP) Technical Pivots with Risk Controls
When (TTNP) Moves Investors should Listen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
LadRx stock logo

LadRx NASDAQ:CYTR

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

aTyr Pharma stock logo

aTyr Pharma NASDAQ:LIFE

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Oncobiologics stock logo

Oncobiologics NASDAQ:OTLK

$1.81 +0.10 (+5.85%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$1.81 0.00 (0.00%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:TROV

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Titan Pharmaceuticals stock logo

Titan Pharmaceuticals NASDAQ:TTNP

$4.40 +0.05 (+1.15%)
As of 07/3/2025 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.